20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	2.04	1.75	1.42
Revenue Growth (YoY)	-	23.03%	-
Cost of Revenue	-	1.39	1.32
Gross Profit	0.64	0.36	0.11
Selling, General & Admin	-	4.76	5.06
Research & Development	-	1.26	1.41
Other Operating Expenses	0	0.02	0.21
Operating Expenses	-	6.04	6.68
Operating Income	-3.68	-5.68	-6.57
Interest Expense (Income)	-0.11	-0.07	-0.18
Other Expense (Income)	0.11	-0.06	0
Pretax Income	-3.68	-5.55	-6.39
Net Income	-3.68	-5.55	-6.39
Free Cash Flow	-1.94	-2.6	-4.52
Gross Margin	31.19%	20.56%	7.66%
Operating Margin	-180.05%	-323.99%	-461.31%
Profit Margin	-180.14%	-316.81%	-448.73%
Free Cash Flow Margin	-95.18%	-148.30%	-317.61%
EBITDA	-3.68	-5.48	-6.4
EBITDA Margin	-180.16%	-312.60%	-449.35%
Depreciation & Amortization	0.11	0.14	0.17
EBIT	-3.79	-5.62	-6.57
EBIT Margin	-185.50%	-320.63%	-461.46%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).